| Trial ID: | L6976 |
| Source ID: | NCT02145611
|
| Associated Drug: |
Glibenclamide
|
| Title: |
Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus|Hypertension|Endothelial Dysfunction
|
| Interventions: |
DRUG: Glibenclamide|DRUG: Vildagliptin
|
| Outcome Measures: |
Primary: Change from baseline in the reactive hyperemia index (RHI) after 12 weeks of vildagliptin x glibenclamide treatment, 12 weeks|Change from baseline in the central blood pressure after 12 weeks of vildagliptin x glibenclamide treatment, 12 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Dr. José Fernando Vilela-Martin MD PhD | Collaborators: Novartis
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2013-07
|
| Completion Date: |
2016-05
|
| Results First Posted: |
|
| Last Update Posted: |
2016-08-16
|
| Locations: |
Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo, 15090-000, Brazil
|
| URL: |
https://clinicaltrials.gov/show/NCT02145611
|
